Related Experiment Video
Updated: Aug 23, 2025

Real-time Observation of the DNA Strand Exchange Reaction Mediated by Rad51
Published on: February 13, 2019
A moving target for drug discovery: Structure activity relationship and many genome (de)stabilizing functions of the
Divya S Bhat1, M Ashley Spies2, Maria Spies1
1Department of Biochemistry, University of Iowa Carver College of Medicine, 51 Newton Road, Iowa City, IA 52242, USA.
Abstract:
BRCA-ness phenotype, a signature of many breast and ovarian cancers, manifests as deficiency in homologous recombination, and as defects in protection and repair of damaged DNA replication forks. A dependence of such cancers on DNA repair factors less important for survival of BRCA-proficient cells, offers opportunities for development of novel chemotherapeutic interventions. The first drugs targeting BRCA-deficient cancers, poly-ADP-ribose polymerase (PARP) inhibitors have been approved for the treatment of advanced, chemotherapy resistant cancers in patients with BRCA1/2 germline mutations. Nine additional proteins that can be targeted to selectively kill BRCA-deficient cancer cells have been identified. Among them, a DNA repair protein RAD52 is an especially attractive target due to general tolerance of the RAD52 loss of function, and protective role of an inactivating mutation. Yet, the effective pharmacological inhibitors of RAD52 have not been forthcoming. In this review, we discuss advances in the state of our knowledge of the RAD52 structure, activities and cellular functions, with a specific focus on the features that make RAD52 an attractive, but difficult drug target.
Insights
BRCA-ness cancers exploit DNA repair defects. Targeting RAD52 offers a novel therapeutic strategy, but developing effective inhibitors remains challenging due to its complex cellular functions.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- BRCA-ness phenotype in breast and ovarian cancers involves homologous recombination deficiency and impaired DNA replication fork repair.
- This creates dependencies on specific DNA repair pathways, presenting therapeutic vulnerabilities.
- Poly-ADP-ribose polymerase (PARP) inhibitors are approved for BRCA-mutated cancers, demonstrating the potential of targeting DNA repair deficiencies.
Approach:
- This review synthesizes current knowledge on the RAD52 protein, a key DNA repair factor.
- It examines RAD52's structure, cellular activities, and functions in DNA repair.
- The focus is on understanding features that make RAD52 a promising yet challenging drug target.
Key Points:
- RAD52 plays a crucial role in DNA repair pathways, particularly in BRCA-deficient cancers.
- Loss of RAD52 function is generally tolerated, and inactivating mutations can be protective.
- Despite its potential as a therapeutic target, effective pharmacological inhibitors for RAD52 are lacking.
Conclusions:
- RAD52 is an attractive target for selectively eliminating BRCA-deficient cancer cells.
- Challenges in developing RAD52 inhibitors stem from its fundamental cellular roles and complex structure.
- Further research into RAD52's biology is essential for advancing novel chemotherapeutic strategies.
Related Concept Videos
Restarting Stalled Replication Forks
DNA Damage can Stall the Cell Cycle
Homologous Recombination
The DNA Replication Fork
Single-Strand DNA Binding Proteins
Negative Regulator Molecules

